Market closed

Viridian Therapeutics/$VRDN

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Viridian Therapeutics

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

Ticker

$VRDN

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Waltham, United States

Employees

Website

www.viridiantherapeutics.com

VRDN Metrics

BasicAdvanced

$1.7B

Market cap

-

P/E ratio

-$4.26

EPS

-

Beta

-

Dividend rate

Price and volume

Market cap

$1.7B

52-week high

$25.21

52-week low

$11.40

Average daily volume

894K

Financial strength

Interest coverage (TTM)

-91.19%

Management effectiveness

Return on assets (TTM)

-32.14%

Return on equity (TTM)

-51.88%

Valuation

Price to revenue (TTM)

4,479.728

Price to book

2.11

Price to tangible book (TTM)

2.11

Growth

Revenue change (TTM)

-12.97%

Earnings per share change (TTM)

-16.49%

3-year revenue growth (CAGR)

-52.42%

3-year earnings per share growth (CAGR)

-39.46%

What the Analysts think about VRDN

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Viridian Therapeutics stock.

VRDN Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

VRDN Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

VRDN News

AllArticlesVideos

Viridian Therapeutics' Superior Prospects Make It A Buy

Seeking Alpha·3 weeks ago

3 Small Biotech Stocks With The 'Big Mo' Right Now

Seeking Alpha·2 months ago

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Business Wire·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VRDN

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Viridian Therapeutics stock?

Viridian Therapeutics (VRDN) has a market cap of $1.7B as of November 13, 2024.

What is the P/E ratio for Viridian Therapeutics stock?

The price to earnings (P/E) ratio for Viridian Therapeutics (VRDN) stock is 0 as of November 13, 2024.

Does Viridian Therapeutics stock pay dividends?

No, Viridian Therapeutics (VRDN) stock does not pay dividends to its shareholders as of November 13, 2024.

When is the next Viridian Therapeutics dividend payment date?

Viridian Therapeutics (VRDN) stock does not pay dividends to its shareholders.

What is the beta indicator for Viridian Therapeutics?

Viridian Therapeutics (VRDN) does not currently have a Beta indicator.